Cytokinetics set to pitch its heart drug to physicians — and Big Pharma suitors

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

I love the Cytokinetics story. There’s so much at stake with aficamten, not to mention all the ups and downs from previous drug-development efforts and now the speculation about a possible takeover. That’s why I invited CEO Robert Blum to sit down with me for a fireside chat at the STAT Breakthrough Summit West in San Francisco on May 16.

Blum and I are going to get into it. I promise this will be a fun and engaging conversation. You might remember that I once short-listed Blum as one of my Worst CEOs of the Year. He certainly does, as he reminded me on a prep call yesterday. I’m going to have to walk that one back, deservedly!

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In